Crocoli Alessandro, Martucci Cristina, Sidro Luca, Delle Donne Daniela, Menna Giuseppe, Pittiruti Mauro, De Pasquale Maria Debora, Strocchio Luisa, Natali Gian Luigi, Inserra Alessandro
Surgical Oncology Unit, Bambino Gesù Children Hospital IRCCS, Rome, Italy.
Department of Anesthesiology and Intensive Care, Santobono-Pausilipon Children Hospital, Naples, Italy.
J Vasc Access. 2023 Jan;24(1):35-40. doi: 10.1177/11297298211009364. Epub 2021 Jun 4.
Proper securement of central venous catheters plays an important role in onco-hematological pediatric patients. A new subcutaneously anchored securement device has been recently introduced in the clinical practice, and it has been extensively used in children.
In our study, we have retrospectively investigated the safety and the effectiveness of such device, reviewing the experience of three Italian pediatric oncological units. We have considered only tunneled catheters (cuffed or non-cuffed) inserted in children with malignancy; all types of tunneled central catheters were included in the analysis (both centrally and peripherally inserted) as long as they were secured with a subcutaneously anchored device. We investigated the incidence of dislodgment and of other catheter-related complications, with special attention to local adverse effects potentially related to the securement device.
We collected data from 311 tunneled catheters of different caliber: 80.4% were centrally inserted central catheters (CICC), 15.4% were peripherally inserted (PICC), and 4.2% were femorally inserted. Approximately half of the catheters (51%) were non-cuffed. Incidence of dislodgment was very low (2.6%) and the incidence of local pain or inflammation potentially related to the securement device was minimal (1.9%). Catheter related bacteremias were below 1 episode/1000 catheter days. No symptomatic catheter related thrombosis was reported. There was no significant difference in complications comparing cuffed versus non-cuffed catheters, or CICCs versus PICCs, or hematologic tumors versus solid tumors.
In our retrospective analysis of a vast population of oncological pediatric patients with tunneled central catheters, the subcutaneously anchored securement device was tolerated very well, and it was highly effective in preventing dislodgment, both in cuffed and non-cuffed catheters.
正确固定中心静脉导管在儿科肿瘤血液学患者中起着重要作用。一种新型皮下锚定固定装置最近已引入临床实践,并已在儿童中广泛使用。
在我们的研究中,我们回顾性调查了该装置的安全性和有效性,回顾了三个意大利儿科肿瘤科室的经验。我们仅考虑在恶性肿瘤儿童中插入的隧道式导管(带袖套或不带袖套);只要使用皮下锚定装置固定,所有类型的隧道式中心导管(包括中心插入和外周插入)都纳入分析。我们调查了导管移位和其他与导管相关并发症的发生率,特别关注可能与固定装置相关的局部不良反应。
我们收集了311根不同口径隧道式导管的数据:80.4%为中心插入的中心静脉导管(CICC),15.4%为外周插入(PICC),4.2%为股静脉插入。大约一半的导管(51%)不带袖套。移位发生率非常低(2.6%),可能与固定装置相关的局部疼痛或炎症发生率极低(1.9%)。导管相关菌血症低于1次/1000导管日。未报告有症状的导管相关血栓形成。在比较带袖套与不带袖套导管、CICC与PICC、血液系统肿瘤与实体肿瘤的并发症方面,没有显著差异。
在我们对大量患有隧道式中心导管的儿科肿瘤患者的回顾性分析中,皮下锚定固定装置耐受性良好,在预防带袖套和不带袖套导管移位方面均非常有效。